These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 6189177)

  • 21. Subacute sclerosing panencephalitis.
    Br Med J; 1979 Nov; 2(6198):1096. PubMed ID: 93011
    [No Abstract]   [Full Text] [Related]  

  • 22. Cerebrospinal fluid IgG changes in subacute sclerosing panencephalitis in the various stages of the disease and during isoprinosine therapy.
    Poloni M; Rocchelli B; Lanzi G; Rosano Burgio F; Besana D
    Ital J Neurol Sci; 1981 May; 2(2):177-84. PubMed ID: 6174478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic experiences with the immunostimulator inosine pranobex].
    Darlath W; Wybran J
    Fortschr Med; 1984 Oct; 102(37):932-4. PubMed ID: 6209193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SSPE incidence, therapy receive renewed attention.
    Gunby P
    JAMA; 1981 Aug; 246(9):927, 931-2. PubMed ID: 6166765
    [No Abstract]   [Full Text] [Related]  

  • 25. Current developments in the management of subacute sclerosing panencephalitis.
    Panagariya A; Sureka RK; Aurora A
    J Assoc Physicians India; 1998 Feb; 46(2):218-20. PubMed ID: 11273118
    [No Abstract]   [Full Text] [Related]  

  • 26. [Subacute sclerosing panencephalitis].
    Aguiar T
    Acta Med Port; 2000; 13(4):193-8. PubMed ID: 11155486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of subacute sclerosing panencephalitis: an overview.
    Taylor WJ; DuRant RH; Dyken PR
    Drug Intell Clin Pharm; 1984 May; 18(5):375-81. PubMed ID: 6202474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoprinosine in subacute sclerosing panencephalitis.
    Huttenlocher PR; Mattson RH
    Neurology; 1979 Jun; 29(6):763-71. PubMed ID: 88024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subacute sclerosing panencephalitis - clinical observations].
    Filipowicz A; Motta E; Piekarska-Konstanty A; Kazibutowska Z
    Pediatr Pol; 1983 May; 58(5):471-5. PubMed ID: 6195590
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis--a multi-institutional collaborative study--The Inosiplex-SSPE Research Committee.
    Fukuyama Y; Nihei K; Matsumoto S; Ebina T; Kamoshita S; Sato T; Arima M; Yabuuchi H; Ueda S; Ohtahara S
    Brain Dev; 1987; 9(3):270-82. PubMed ID: 2444125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte subsets, TNF alpha and interleukin-4 levels in treated and untreated subacute sclerosing panencephalitis patients.
    Anlar B; Guven A; Köse G; Okur H; Kose O; Aydin OF; Kabakus N; Altunbasak S; Herguner O; Sonmez M; Serdaroglu A
    J Neuroimmunol; 2005 Jun; 163(1-2):195-8. PubMed ID: 15885323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraventricular administration of interferon and administration of methisoprinol by mouth in the treatment of adult-onset subacute sclerosing panencephalitis.
    Harbord MG; Jones T; Hicks EP; Blumbergs PC
    Med J Aust; 1988 May; 148(9):467-9, 473. PubMed ID: 2452337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients.
    Jones CE; Dyken PR; Huttenlocher PR; Jabbour JT; Maxwell KW
    Lancet; 1982 May; 1(8280):1034-7. PubMed ID: 6176821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical registers as historical controls: analysis of an open clinical trial of inosiplex in subacute sclerosing panencephalitis.
    Hoehler FK; Mantel N; Gehan E; Kahana E; Alter M
    Stat Med; 1984; 3(3):225-37. PubMed ID: 6207580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of a patient with SSPE].
    Goetz O; Peller P
    Monatsschr Kinderheilkd (1902); 1980 May; 128(5):246-7. PubMed ID: 6158679
    [No Abstract]   [Full Text] [Related]  

  • 36. Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS.
    Anlar B
    Neurology; 2007 Apr; 68(17):1438; author reply 1438. PubMed ID: 17452596
    [No Abstract]   [Full Text] [Related]  

  • 37. Subacute sclerosing panencephalitis.
    Gascon GG; Crowell J; Stigsby B; Yamani S
    Neurology; 1993 Feb; 43(2):454-5. PubMed ID: 7679784
    [No Abstract]   [Full Text] [Related]  

  • 38. The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis.
    DuRant RH; Dyken PR; Swift AV
    J Pediatr; 1982 Aug; 101(2):288-93. PubMed ID: 6178812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inosiplex: antiviral, immunomodulator, or neither?
    Lancet; 1982 May; 1(8280):1052-4. PubMed ID: 6176822
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary results for treatments in subacute sclerosing panencephalitis have problems?
    Anlar B
    J Child Neurol; 2004 Jun; 19(6):463; author reply 463-4. PubMed ID: 15446398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.